Cargando…

Health-Related Quality of Life of Patients with Acute Myeloid Leukemia: A Systematic Literature Review

INTRODUCTION: Patients with acute myeloid leukemia (AML), especially those with relapsed or refractory AML, have poor clinical prognosis and outcomes. Health-related quality of life (HRQoL) assessments have become increasingly important in oncology, aiding in identifying and informing supportive the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korol, Ellen E., Wang, Sisi, Johnston, Karissa, Ravandi-Kashani, Farhad, Levis, Mark, van Nooten, Floortje
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488112/ https://www.ncbi.nlm.nih.gov/pubmed/28680951 http://dx.doi.org/10.1007/s40487-016-0039-6

Ejemplares similares

The Patient Perspective on Living with Acute Myeloid Leukemia
por: Tomaszewski, Erin L., et al.
Publicado: (2016)

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
por: Abbas, Hussein A, et al.
Publicado: (2019)

Acute Myeloid Leukemia as a Model for Cancer Therapy
por: Ravandi, Farhad
Publicado: (2012)

Maintenance therapy in acute myeloid leukemia: advances and controversies
por: Senapati, Jayastu, et al.
Publicado: (2023)

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
por: Daver, Naval, et al.
Publicado: (2021)

Advances in treating acute myeloid leukemia
por: Showel, Margaret M., et al.
Publicado: (2014)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?
por: Short, Nicholas J., et al.
Publicado: (2019)

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
por: Short, Nicholas J., et al.
Publicado: (2019)

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
por: Briski, Robert, et al.
Publicado: (2023)

Potential targeting of FLT3 acute myeloid leukemia
por: Ambinder, Alexander J., et al.
Publicado: (2020)

The clinical impact of the molecular landscape of acute myeloid leukemia
por: Kayser, Sabine, et al.
Publicado: (2023)

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
por: Aitken, Marisa J. L., et al.
Publicado: (2021)

Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Acute myeloid leukemia: current progress and future directions
por: Kantarjian, Hagop, et al.
Publicado: (2021)

Neutropenic Enterocolitis: An Uncommon, but Fearsome Complication of Leukemia
por: Babakhanlou, Rodrick, et al.
Publicado: (2023)

Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia
por: Eriksson, Daniel, et al.
Publicado: (2016)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group
por: Nagarajan, Rajaram, et al.
Publicado: (2019)

Acute promyelocytic leukemia current treatment algorithms
por: Yilmaz, Musa, et al.
Publicado: (2021)

Immunotherapy in Acute Myeloid Leukemia: Where We Stand
por: Isidori, Alessandro, et al.
Publicado: (2021)

Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
por: Yilmaz, Musa, et al.
Publicado: (2019)

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia
por: Senapati, Jayastu, et al.
Publicado: (2022)

Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review
por: Forsythe, Anna, et al.
Publicado: (2019)

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia
por: Khan, Maliha, et al.
Publicado: (2017)

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
por: Bidikian, Aram, et al.
Publicado: (2022)

Characterizing the Health-Related Quality of Life Burden of Overactive Bladder Using Disease-Specific Patient-Reported Outcome Measures: A Systematic Literature Review
por: Johnston, Karissa M., et al.
Publicado: (2019)

Editorial: Acute Promyelocytic Leukemia — Towards A Chemotherapy-Free Approach to Cure in All Patients
por: Gill, Harinder, et al.
Publicado: (2022)

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype
por: Samra, Bachar, et al.
Publicado: (2020)

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
por: Wang, Feng, et al.
Publicado: (2021)

P509: THE IMPACT OF THE NUMBER OF RAS MUTATIONS IN THE OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED FRONTLINE AT A SINGLE INSTITUTION.
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
por: Daver, Naval, et al.
Publicado: (2022)

Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada
por: Cressman, Sonya, et al.
Publicado: (2020)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
por: Swaminathan, Mahesh, et al.
Publicado: (2021)

Validated Instruments of Quality of Life (QOL) in Patients With Acute Myeloid Leukemia (AML) and Other Cancers
por: Salas, Maribel, et al.
Publicado: (2020)

Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
por: Loghavi, Sanam, et al.
Publicado: (2014)

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
por: Ravandi, Farhad, et al.
Publicado: (2023)

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
por: Samra, Bachar, et al.
Publicado: (2020)

Formaldehyde Exposure and Acute Myeloid Leukemia: A Review of the Literature
por: Allegra, Alessandro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fj63toq4uo8qup8fcuf0eg5del